SEARCH

SEARCH BY CITATION

References

  • Ahmed T. and Frey J. U. (2005) Phosphodiesterase 4B (PDE4B) and cAMP-level regulation within different tissue fractions of rat hippocampal slices during long-term potentiation in vitro. Brain Res. 1041, 212222.
  • Ariga M., Neitzert B., Nakae S., Mottin G., Bertrand C., Pruniaux M. P., Jin S. L. and Conti M. (2004) Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation. J. Immunol. 173, 75317538.
  • Atkins C. M., Oliva A. A. Jr., Alonso O. F., Chen S., Bramlett H. M., Hu B. R. and Dietrich W. D. (2007a) Hypothermia treatment potentiates ERK1/2 activation after traumatic brain injury. Eur. J. Neurosci. 26, 810819.
  • Atkins C. M., Oliva A. A. Jr., Alonso O. F., Pearse D. D., Bramlett H. M. and Dietrich W. D. (2007b) Modulation of the cAMP signaling pathway after traumatic brain injury. Exp. Neurol. 208, 145158.
  • Atkins C. M., Kang Y., Furones C., Truettner J. S., Alonso O. F. and Dietrich W. D. (2012) Postinjury treatment with rolipram increases hemorrhage after traumatic brain injury. J. Neurosci. Res. 90, 18611871.
  • Block F., Schmidt W., Nolden-Koch M. and Schwarz M. (2001) Rolipram reduces excitotoxic neuronal damage. NeuroReport 12, 15071511.
  • Bruno O., Romussi A., Spallarossa A., Brullo C., Schenone S., Bondavalli F., Vanthuyne N. and Roussel C. (2009) New selective phosphodiesterase 4D inhibitors differently acting on long, short, and supershort isoforms. J. Med. Chem. 52, 65466557.
  • Bruno O., Fedele E., Prickaerts J. et al. (2011) GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses. Br. J. Pharmacol. 164, 20542063.
  • Burgin A. B., Magnusson O. T., Singh J. et al. (2010) Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat. Biotechnol. 28, 6370.
  • Conti M. and Beavo J. (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu. Rev. Biochem. 76, 481511.
  • Dietrich W. D., Chatzipanteli K., Vitarbo E., Wada K. and Kinoshita K. (2004) The role of inflammatory processes in the pathophysiology and treatment of brain and spinal cord trauma. Acta Neurochir. Suppl. 89, 6974.
  • Dixon C. E., Kraus M. F., Kline A. E., Ma X., Yan H. Q., Griffith R. G., Wolfson B. M. and Marion D. W. (1999) Amantadine improves water maze performance without affecting motor behavior following traumatic brain injury in rats. Restor. Neurol. Neurosci. 14, 285294.
  • D'Sa C., Tolbert L. M., Conti M. and Duman R. S. (2002) Regulation of cAMP-specific phosphodiesterases type 4B and 4D (PDE4) splice variants by cAMP signaling in primary cortical neurons. J. Neurochem. 81, 745757.
  • Fatemi S. H., King D. P., Reutiman T. J., Folsom T. D., Laurence J. A., Lee S., Fan Y. T., Paciga S. A., Conti M. and Menniti F. S. (2008a) PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia. Schizophr. Res. 101, 3649.
  • Fatemi S. H., Reutiman T. J., Folsom T. D. and Lee S. (2008b) Phosphodiesterase-4A expression is reduced in cerebella of patients with bipolar disorder. Psychiatr. Genet. 18, 282288.
  • Giampa C., Laurenti D., Anzilotti S., Bernardi G., Menniti F. S. and Fusco F. R. (2010) Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease. PLoS ONE 5, e13417.
  • Grond-Ginsbach C., Hummel M., Wiest T., Horstmann S., Pfleger K., Hergenhahn M., Hollstein M., Mansmann U., Grau A. J. and Wagner S. (2008) Gene expression in human peripheral blood mononuclear cells upon acute ischemic stroke. J. Neurol. 255, 723731.
  • Hill E. V., Sheppard C. L., Cheung Y. F., Gall I., Krause E. and Houslay M. D. (2006) Oxidative stress employs phosphatidyl inositol 3-kinase and ERK signalling pathways to activate cAMP phosphodiesterase-4D3 (PDE4D3) through multi-site phosphorylation at Ser239 and Ser579. Cell. Signal. 18, 20562069.
  • Iona S., Cuomo M., Bushnik T., Naro F., Sette C., Hess M., Shelton E. R. and Conti M. (1998) Characterization of the rolipram-sensitive, cyclic AMP-specific phosphodiesterases: identification and differential expression of immunologically distinct forms in the rat brain. Mol. Pharmacol. 53, 2332.
  • Jin S. L. and Conti M. (2002) Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses. Proc. Natl Acad. Sci. USA 99, 76287633.
  • Lakics V., Karran E. H. and Boess F. G. (2010) Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 59, 367374.
  • Li W., Dai S., An J. et al. (2008) Chronic but not acute treatment with caffeine attenuates traumatic brain injury in the mouse cortical impact model. Neuroscience 151, 11981207.
  • Li L. X., Cheng Y. F., Lin H. B., Wang C., Xu J. P. and Zhang H. T. (2011a) Prevention of cerebral ischemia-induced memory deficits by inhibition of phosphodiesterase-4 in rats. Metab. Brain Dis. 26, 3747.
  • Li Y. F., Cheng Y. F., Huang Y., Conti M., Wilson S. P., O'Donnell J. M. and Zhang H. T. (2011b) Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling. J. Neurosci. 31, 172183.
  • MacKenzie S. J., Baillie G. S., McPhee I., MacKenzie C., Seamons R., McSorley T., Millen J., Beard M. B., van Heeke G. and Houslay M. D. (2002) Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1). Br. J. Pharmacol. 136, 421433.
  • Manning C. D., Burman M., Christensen S. B., Cieslinski L. B., Essayan D. M., Grous M., Torphy T. J. and Barnette M. S. (1999) Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br. J. Pharmacol. 128, 13931398.
  • Medina A. E. (2011) Therapeutic utility of phosphodiesterase type I inhibitors in neurological conditions. Front. Neurosci. 5, 21.
  • Mehats C., Jin S. L., Wahlstrom J., Law E., Umetsu D. T. and Conti M. (2003) PDE4D plays a critical role in the control of airway smooth muscle contraction. FASEB J. 17, 18311841.
  • Michibata H., Yanaka N., Kanoh Y., Okumura K. and Omori K. (2001) Human Ca2+ /calmodulin-dependent phosphodiesterase PDE1A: novel splice variants, their specific expression, genomic organization, and chromosomal localization. Biochim. Biophys. Acta 1517, 278287.
  • Miro X., Perez-Torres S., Puigdomenech P., Palacios J. M. and Mengod G. (2002) Differential distribution of PDE4D splice variant mRNAs in rat brain suggests association with specific pathways and presynaptical localization. Synapse 45, 259269.
  • Miwa T., Mori A., Nakahara T. and Ishii K. (2009) Intravenously administered phosphodiesterase 4 inhibitors dilate retinal blood vessels in rats. Eur. J. Pharmacol. 602, 112116.
  • Morganti-Kossmann M. C., Satgunaseelan L., Bye N. and Kossmann T. (2007) Modulation of immune response by head injury. Injury 38, 13921400.
  • Nikulina E., Tidwell J. L., Dai H. N., Bregman B. S. and Filbin M. T. (2004) The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery. Proc. Natl Acad. Sci. USA 101, 87868790.
  • Oliva A. A. Jr., Kang Y., Sanchez-Molano J., Furones C. and Atkins C. M. (2012) STAT3 signaling after traumatic brain injury. J. Neurochem. 120, 710720.
  • Pearse D. D., Pereira F. C., Marcillo A. E., Bates M. L., Berrocal Y. A., Filbin M. T. and Bunge M. B. (2004) cAMP and Schwann cells promote axonal growth and functional recovery after spinal cord injury. Nat. Med. 10, 610616.
  • Reneerkens O. A., Rutten K., Steinbusch H. W., Blokland A. and Prickaerts J. (2009) Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology 202, 419443.
  • Reyes-Irisarri E., Sanchez A. J., Garcia-Merino J. A. and Mengod G. (2007) Selective induction of cAMP phosphodiesterase PDE4B2 expression in experimental autoimmune encephalomyelitis. J. Neuropathol. Exp. Neurol. 66, 923931.
  • Robichaud A., Savoie C., Stamatiou P. B., Lachance N., Jolicoeur P., Rasori R. and Chan C. C. (2002) Assessing the emetic potential of PDE4 inhibitors in rats. Br. J. Pharmacol. 135, 113118.
  • Seeger T. F., Bartlett B., Coskran T. M. et al. (2003) Immunohistochemical localization of PDE10A in the rat brain. Brain Res. 985, 113126.
  • Shin S. S., Bray E. R., Zhang C. Q. and Dixon C. E. (2011) Traumatic brain injury reduces striatal tyrosine hydroxylase activity and potassium-evoked dopamine release in rats. Brain Res. 1369, 208215.
  • Suda S., Nibuya M., Ishiguro T. and Suda H. (1998) Transcriptional and translational regulation of phosphodiesterase type IV isozymes in rat brain by electroconvulsive seizure and antidepressant drug treatment. J. Neurochem. 71, 15541563.
  • Sun D. A., Deshpande L. S., Sombati S., Baranova A., Wilson M. S., Hamm R. J. and DeLorenzo R. J. (2008) Traumatic brain injury causes a long-lasting calcium (Ca2+ )-plateau of elevated intracellular Ca levels and altered Ca2+  homeostatic mechanisms in hippocampal neurons surviving brain injury. Eur. J. Neurosci. 27, 16591672.
  • Temple M. D., Delahunty T. M., Hamm R. J., Phillips L. L., Lyeth B. G. and Povlishock J. T. (2001) Subtle alterations in NMDA-stimulated cyclic GMP levels following lateral fluid percussion brain injury. J. Neurotrauma 18, 4755.
  • Tilley D. G. and Maurice D. H. (2002) Vascular smooth muscle cell phosphodiesterase (PDE) 3 and PDE4 activities and levels are regulated by cyclic AMP in vivo. Mol. Pharmacol. 62, 497506.
  • Verghese M. W., McConnell R. T., Strickland A. B., Gooding R. C., Stimpson S. A., Yarnall D. P., Taylor J. D. and Furdon P. J. (1995) Differential regulation of human monocyte-derived TNF α and IL-1 β by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. J. Pharmacol. Exp. Ther. 272, 13131320.
  • Willette R. N., Shiloh A. O., Sauermelch C. F., Sulpizio A., Michell M. P., Cieslinski L. B., Torphy T. J. and Ohlstein E. H. (1997) Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors. J. Cereb. Blood Flow Metab. 17, 210219.
  • Williams G., Morris M. E., Schache A. and McCrory P. R. (2009) Incidence of gait abnormalities after traumatic brain injury. Arch. Phys. Med. Rehabil. 90, 587593.
  • Yan C., Bentley J. K., Sonnenburg W. K. and Beavo J. A. (1994) Differential expression of the 61 kDa and 63 kDa calmodulin-dependent phosphodiesterases in the mouse brain. J. Neurosci. 14, 973984.
  • Zhang B., Yang L., Konishi Y., Maeda N., Sakanaka M. and Tanaka J. (2002a) Suppressive effects of phosphodiesterase type IV inhibitors on rat cultured microglial cells: comparison with other types of cAMP-elevating agents. Neuropharmacology 42, 262269.
  • Zhang H. T., Huang Y., Jin S. L., Frith S. A., Suvarna N., Conti M. and O'Donnell J. M. (2002b) Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology 27, 587595.